Eikon Therapeutics, Inc.
- EIKN · Nasdaq
- Biological Products, (No Diagnostic Substances)
- Millbrae, CA
- 384 employees
- CIK 0001861123
Updated from SEC filings through
Top things to know
Executives
-
Roger M. Perlmutter Chief Executive Officer, Chair and Director 10-K, March 30, 2026 - Alfred Bowie Chief Financial Officer 10-K, March 30, 2026
- Michael Klobuchar Chief Operating Officer 10-K, March 30, 2026
- Benjamin Thorner Chief Business Officer and General Counsel 10-K, March 30, 2026
- Roy Baynes Chief Medical Officer 10-K, March 30, 2026
Eikon Therapeutics, Inc. is a U.S. public company in biological products, (no diagnostic substances) (SIC 2836), headquartered in Millbrae, CA. It trades as EIKN on Nasdaq. It reported about 384 employees.
Five-year financials
We have no annual financials for this company yet.
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| | Chief Executive Officer, Chair and Director | 10-K, March 30, 2026 |
| Alfred Bowie | Chief Financial Officer | 10-K, March 30, 2026 |
| Michael Klobuchar | Chief Operating Officer | 10-K, March 30, 2026 |
| Benjamin Thorner | Chief Business Officer and General Counsel | 10-K, March 30, 2026 |
| Roy Baynes | Chief Medical Officer | 10-K, March 30, 2026 |
| David Meline | Director | 10-K, March 30, 2026 |
| Joshua Wolfe | Director | 10-K, March 30, 2026 |
| Kenneth C. Frazier | Director | 10-K, March 30, 2026 |
| Leon Chen | Director | 10-K, March 30, 2026 |
| Robert Huffines | Director | 10-K, March 30, 2026 |
What Eikon Therapeutics, Inc. does
Eikon is a late-stage clinical biopharmaceutical company dedicated to building a global, fully integrated organization developing innovative medicines to address serious unmet medical needs. Eikon’s initial focus is oncology, where it is advancing a pipeline of drug candidates targeting areas of high unmet need that could eventually become critical medicines for the treatment of various cancers.
Press release "About" paragraph, 10-K for the year ending October 26, 2026
Shares and governance
| Shares outstanding | 54.2 million (as of November 2, 2026) | 10-Q, November 12, 2026 |
|---|---|---|
| Reportable segments | 1 (period ending September 30, 2026) | 10-Q, November 12, 2026 |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| February 4, 2026 | Kenneth C. Frazier Director | Buy | 111,111 | $2.0M | Form 4, February 6, 2026 |
| February 4, 2026 | Josh Wolfe Director | Buy | 277,776 | $5.0M | Form 4, February 6, 2026 |
| February 4, 2026 | Josh Wolfe Director | Buy | 277,776 | $5.0M | Form 4, February 6, 2026 |
Recent 8-K events
- 8-K filed 2026-11-12
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-10-26
- Item 7.01 Regulation FD disclosure
- Item 8.01 Other events
- 8-K filed 2026-10-23
- Item 7.01 Regulation FD disclosure
- Item 8.01 Other events
- 8-K filed 2026-08-14
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-08-13
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-08-03
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-06-10
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-06-01
- Item 7.01 Regulation FD disclosure
- Item 8.01 Other events
- 8-K filed 2026-05-11
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-03-30
- Item 2.02 Results of operations and financial condition (earnings release)
Frequently asked questions about Eikon Therapeutics, Inc.
- What does Eikon Therapeutics, Inc. do?
- In its own words, from Item 1 of its 10-K: "Eikon is a late-stage clinical biopharmaceutical company dedicated to building a global, fully integrated organization developing innovative medicines to address serious unmet medical needs. Eikon’s initial focus is oncology, where it is advancing a pipeline of drug candidates targeting areas of high unmet need that could eventually become critical medicines for the treatment of various cancers."
- How many employees does Eikon Therapeutics, Inc. have?
- About 384 as of December 31, 2025, as stated in its annual report.
- Who is the CFO of Eikon Therapeutics, Inc.?
- Alfred Bowie, Chief Financial Officer, as named in a 10-K filed March 30, 2026.
- Where is Eikon Therapeutics, Inc. headquartered?
- Millbrae, CA.
- What is Eikon Therapeutics, Inc.'s stock ticker?
- EIKN on Nasdaq.
- What industry is Eikon Therapeutics, Inc. in?
- Biological Products, (No Diagnostic Substances), SIC code 2836.
- What is Eikon Therapeutics, Inc.'s website?
- eikontx.com. Investor relations: https://investors.eikontx.com/.
- When does Eikon Therapeutics, Inc. report earnings next?
- February 11, 2027. This is an estimate from past filing dates, not a confirmed date.
- Is Eikon Therapeutics, Inc. a public company?
- Yes. Eikon Therapeutics, Inc. files with the SEC under CIK 0001861123 and trades as EIKN.
- How many shares of Eikon Therapeutics, Inc. are outstanding?
- 54.2 million shares as of November 2, 2026, from its 10-Q filed November 12, 2026.
- How many business segments does Eikon Therapeutics, Inc. report?
- 1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 12, 2026.
- Have Eikon Therapeutics, Inc. insiders traded stock recently?
- Since February 4, 2026, officers and directors reported 0 open-market sales and 3 purchases worth about $12.0M on Forms 4 and 5. The most recent: Kenneth C. Frazier (Director) bought 111,111 shares on February 4, 2026.